Interstitial Cystitis Clinical Trial
Official title:
Efficacy of Peppermint Oil in a Randomized, Single-Blind, Placebo Controlled Trial in Women With Interstitial Cystitis/Bladder Pain Syndrome
The purpose of this study is to assess the use of peppermint oil as a treatment for Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS).
Status | Recruiting |
Enrollment | 100 |
Est. completion date | December 2023 |
Est. primary completion date | June 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Women ages 18-65 years old - Diagnosed with IC/BPS for at least one month prior to study enrollment Exclusion Criteria: - Culture proven urinary tract infection within 1 month of randomization - Gross hematuria - Currently pregnant or breastfeeding - Unable to speak and read English - History of allergic reaction to peppermint, coconut or enteric coating - History of malabsorption syndrome - History of gastroparesis - History of gastric bypass surgery - History of gastrointestinal, genitourinary or pelvic cancer in the last 5 years - History of insulin dependent diabetes - History of active urinary stone disease |
Country | Name | City | State |
---|---|---|---|
United States | Springs Medical Center | Louisville | Kentucky |
Lead Sponsor | Collaborator |
---|---|
University of Louisville | Integrative Therapeutics, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | O'Leary/Sant questionnaire scores | Participant responses to the O'Leary/Sant questionnaire assessing IC/BPS symptoms will be compared at baseline and after starting treatment with peppermint oil. | 8 weeks | |
Primary | Pelvic Pain and Urgency/Frequency questionnaire scores | Participant responses to the Pelvic Pain and Urgency/Frequency questionnaire assessing IC/BPS symptoms will be compared at baseline and after starting treatment with peppermint oil. | 8 weeks | |
Secondary | Urine pH | Changes in urine pH on urine dipstick from clinically indicated lab collections at the time of office visits during the study period | 8 weeks | |
Secondary | Incidence of urinary tract infections (UTIs) | Culture proven UTIs during the study period (>100,000 CFU of a single pathogen) | 8 weeks | |
Secondary | Additional IC/BPS Treatments received | Number and type of additional IC/BPS each participant undergoes | 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04313972 -
IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone
|
Phase 4 | |
Completed |
NCT03282318 -
A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis
|
Phase 2 | |
Completed |
NCT03463499 -
The Efficacy and Safety of Intravesical Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients
|
N/A | |
Completed |
NCT02898220 -
Trans-MAPP II Study of Urologic Chronic Pelvin Pain
|
||
Terminated |
NCT02591199 -
Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
|
Phase 2 | |
Completed |
NCT02247557 -
Intravesical Instillation of Liposome Encapsulated Botulinum Toxin A (Lipotoxin) in Treatment of Interstitial Cystitis
|
Phase 2 | |
Active, not recruiting |
NCT01731470 -
Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)
|
N/A | |
Completed |
NCT01197261 -
OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS)
|
Phase 2 | |
Completed |
NCT00971568 -
Urinary Biomarkers Characteristic to Interstitial Cystitis
|
N/A | |
Completed |
NCT00527917 -
A Pilot Clinical Investigation of the Efficacy and Safety of Uracyst® Versus Placebo in Patients With Interstitial Cystitis/Painful Bladder Syndrome.
|
Phase 2 | |
Completed |
NCT00150488 -
URACYST® For the Treatment of GAG Deficient Interstitial Cystitis
|
N/A | |
Recruiting |
NCT00094874 -
Acupuncture for the Treatment of Interstitial Cystitis (IC) Symptoms
|
Phase 3 | |
Terminated |
NCT00086684 -
Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis
|
Phase 4 | |
Completed |
NCT04401176 -
Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome
|
Phase 2 | |
Recruiting |
NCT05147779 -
Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Interstitial Cystitis
|
Phase 1 | |
Suspended |
NCT04450316 -
Low-dose Naltrexone for Bladder Pain Syndrome
|
Phase 2 | |
Completed |
NCT04010513 -
Hypnosis for Bladder Pain Syndrome
|
N/A | |
Completed |
NCT05179460 -
A Study of Pentosan Polysulfate Sodium and the Development of Pigmentary Maculopathy and Pigmentary Retinopathy
|
||
Completed |
NCT02232282 -
Acupuncture for Female IC/PBSyndrome and Its Effect on the Urinary Microbiome: A Randomized Controlled Trial
|
N/A | |
Completed |
NCT00546858 -
Relationship of Interstitial Cystitis to Vulvodynia
|
N/A |